

The importance of considering competing treatment affecting prognosis in the evaluation of therapy in trials: the example of renal transplantation in hemodialysis trials

C. Marijn Hazelbag (1), Sanne A.E. Peters (1,2), Peter J. Blankestijn (15), Michiel L. Bots (1), Bernard Canaud (3,4), Andrew Davenport (5), Muriel P.C. Grooteman (6), Fatih Kircelli (7), Francesco Locatelli (8), Francisco Maduell (9), Marion Morena (4,10), Menso J. Nubé (6), Ercan Ok (7), Ferran Torres (11,12), Arno W. Hoes (1), Rolf H.H. Groenwold (1), on behalf of the HDF pooling project investigators

(1). Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht, The Netherlands

(2). The George Institute for Global Health, University of Oxford, Oxford, UK

(3). Nephrology, Dialysis and Intensive Care Unit, CHRU, Montpellier, France;

(4). Dialysis Research and Training Institute, Montpellier, France

(5). University College London, Centre for Nephrology, Royal Free Hospital, London, United Kingdom

(6). Department of Nephrology, VU University Medical Center, Amsterdam, The Netherlands

(7). Division of Nephrology, Ege University School of Medicine, Izmir, Turkey

(8). Department of Nephrology, Alessandro Manzoni Hospital, Lecco, Italy

(9). Nephrology Department, Hospital Clinic, Barcelona, Spain

(10). Biochemistry and Hormonology Department Laboratory, CHRU, Montpellier, France;

PhyMedExp, University of Montpellier, ISERM U1046, CNRS UMR 9214, Montpellier, France

(11). Biostatistics Unit, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain

(12). Biostatistics and Data Management Platform, IDIBAPS, Hospital Clinic, Barcelona, Spain

(13). The George Institute for Global Health, University of Sydney, Sydney, Australia;

(15). Department of Nephrology, University Medical Center Utrecht, Utrecht; The Netherlands

Corresponding author:

C. Marijn Hazelbag, MSc

Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht

POBOX 85500, 3508 GA, Utrecht, The Netherlands

Tel. +31 88 755 5110; Fax. +31 88 756 8099;

E-mail: c.m.hazelbag@umcutrecht.nl

ABSTRACT

Background: During the follow-up in a randomized controlled trial, participants may receive additional (non-randomly allocated) treatment that affects the outcome. Typically, such additional treatment is not taken into account in the evaluation of the results. Two pivotal trials of the effects of hemodiafiltration (HDF) versus hemodialysis (HD) on mortality in patients with end-stage renal disease reported differing results. We set out to evaluate to what extent methods to take other treatments (i.e. renal transplantation) into account may explain the difference in findings between RCTs. This is illustrated using a clinical example of two RCTs estimating the effect of HDF versus HD on mortality.

Methods: Using individual patient data from the ESHOL (n=902) and CONTRAST (n=714) trials, five methods for estimating the effect of HDF versus HD on all-cause mortality were compared: intention-to-treat (ITT) analysis (i.e., not taking renal transplantation into account), per protocol exclusion (PP_{excl} ; exclusion of patients who receive transplantation), PP_{cens} (censoring patients at time of transplantation), transplantation-adjusted (TA) analysis, and an extension of the TA analysis (TA_{ext}) by additional adjustment for variables related to both risk of receiving a transplantation and the risk of an outcome (transplantation-outcome confounders). Cox proportional hazards models were applied.

Results: Unadjusted ITT analysis of all-cause mortality led to differing results between CONTRAST and ESHOL: HR 0.95 (95%CI 0.75-1.20) and HR 0.76 (95%CI 0.59-0.97), respectively: difference between 5% and 24% risk reduction. Similar differences between the two trials were observed for the other unadjusted analytical methods (PP_{cens} , PP_{excl} , TA). The HRs of HDF versus HD treatment became more similar after adding transplantation as a time varying covariate and including transplantation-outcome confounders: HR 0.89 (95%CI 0.69-1.13) in CONTRAST and HR 0.80 (95%CI 0.62-1.02) in ESHOL.

Conclusions: The apparent differences in estimated treatment effects between two dialysis trials were to a large extent attributable to differences in applied methodology for taking renal transplantation into account in their final analyses. Our results exemplify the necessity of careful consideration of the treatment effect of interest when estimating therapeutic effect in randomized controlled trials in which participants may receive additional treatments.

Keywords: end-stage renal disease – hemodiafiltration – randomized controlled trial – renal transplantation – time-varying exposure

Short summary

- Methods for handling competing treatments in trials lead to effect estimates with differing causal interpretations.
- In order to obtain an effect estimate for a therapy that is independent of the effect a therapy has through affecting (the probability of) another treatment, researchers should include competing treatment as a time-varying covariate in the model for the outcome.
- When competing treatment is included as a time-varying covariate in the model for the outcome, researchers should also adjust for variables related to both competing treatment and the outcome (TA_{ext}).
- This approach explained to a large extent the differences in results between ESHOL and CONTRAST studies, i.e., a difference between RCT results in relative risk reduction of 19% was reduced to 9%.

INTRODUCTION

The randomized controlled trial (RCT) is the preferred design to assess the effects of medical treatments. When patients switch to the other trial treatment arm, receive additional treatment that is not randomly allocated, or stop their treatment, estimation of treatment effects may not be straightforward, notably when treatment switching depends on patient characteristics [1].

In RCTs comparing hemodiafiltration (HDF) with hemodialysis (HD) on the risk of mortality among patients with end stage kidney disease (ESKD), during follow-up a subset of patients may receive another (non-randomly allocated) treatment that effectively improves patient outcome. For example, renal transplantation is highly effective in reducing mortality risk in ESKD patients and differences in handling renal transplantation during follow-up in the analysis of a trial may lead to different results [2]. Two pivotal dialysis trials reported conflicting findings: results of the ESHOL trial indicated improved survival for HDF compared to HD (all-cause mortality HR 0.70; 95%CI 0.53-0.92), while results from the CONTRAST analysis reported no difference in mortality between treatment groups (HR 0.95; 95%CI 0.75-1.20) [3, 4]. These differing results may be explained by a number of differences between the trials. Notably, in the original ESHOL study patients were censored at the time of renal transplantation, so no patient information on all-cause mortality was collected after renal transplantation. [4]. Such loss to follow-up may introduce bias if censoring is associated with the allocated treatment and the risk of the outcome [1, 5]. Alternatively, in the CONTRAST trial participants were followed-up for the primary outcome (i.e. all-cause mortality), irrespective of a renal transplantation and the effects of the dialysis treatments were estimated based on an intention-to-treat analysis (and ignoring transplantation) [3]. Furthermore, none of the trial analyses took renal transplantation into account.

Post-randomization renal transplantation may induce differences in patient characteristics between treatment groups in dialysis trials, since the probability of receiving a renal transplantation may not only depend on patient characteristics, but also on the randomly allocated treatment a patient receives (here: on the dialysis modality). For example, patients treated with HDF may more often receive a renal transplant compared to patients treated with HD (e.g. when HDF brings patients in a better shape for transplantation). As a result, in dialysis trials, the probability of receiving a transplant may differ between treatment arms. Therefore, restricting the analysis to those who did not undergo a renal transplantation (e.g. in a per protocol analysis), may result in incomparable treatment groups. As an example, assume that 20% of HDF treated patients receives a renal transplantation, compared to 10% of HD treated patients and that transplantation is more likely in younger patients. Due to the randomization procedure, the age distribution at baseline of patients

receiving HDF or HD is comparable. However, restricting the analysis to those patients who did not undergo a renal transplantation, leads to excluding a larger proportion (20%) of patients (who are on average younger) in the HDF treatment group, compared to the (10%) of patients in the HD treatment group. The remaining patients in the HDF treatment group are on average older than the patients in the HD treatment group, a situation referred to as confounding, because age is now associated with treatment as well as the outcome (here: survival).

In other words, if treatment increases the probability to receive a renal transplant and risk factors for the outcome (mortality) are also related to receiving renal transplantation, restricting the data analysis to those patients who did not receive a transplantation (or similarly, adjusting for transplantation) may distort the balance between treatment groups achieved by randomization (See Figure 1). If the selection of patients for the analysis (e.g. non-transplanted patients) differs between treatment groups (i.e. if patients in one of the two comparison groups are more likely to receive transplantation), the effect estimate will be biased [6]. When the assigned treatment is, however, not related to the competing treatment (renal transplantation), but the competing treatment does affect the absolute risk of the outcome (survival), generally the relative risk will be correct, although the precision of the estimate is reduced (i.e., larger confidence intervals). A priori we did not know whether transplantation rates would differ between treatment arms. However, since transplantation is a very effective competing treatment, we expected that even slight differences (e.g. due to chance) could influence results.

When the mechanism of allocating transplant kidneys differs between studies, this may contribute to differences in effect estimates between studies depending on the applied method of analysis. To study the value of taking competing risks into account when evaluating therapy effect, we set out to determine to what extent approaches that take competing risks (i.e., renal transplantation) into account may explain the conflicting findings between these two trials.

SUBJECTS AND METHODS

Data design and study population

Individual patient data from the CONTRAST and ESHOL studies were used for the current study. Detailed descriptions of the study designs, patient characteristics, and treatment procedures of each of the studies have been reported elsewhere [3][4][7][8]. In the ESHOL study patients who received a renal transplant had been censored alive in the previously published analyses, an approach potentially leading to bias. The ESHOL dataset was completed by adding follow-up data on all-cause mortality for those patients who had discontinued randomized treatment (received a renal transplant), as described previously [7][9Error! Reference source not found.]. The ESHOL study included 906 patients; 456 were randomized to receive HDF and 450 to HD. Median follow-up time was 3 years (range 0.01, 3.08) [4]. The CONTRAST study included 714 patients; 358 received HDF and 356 were allocated to HD. Median follow-up time was 2.90 years (range 0.04-6.56) [3]. Due to missing outcome and time of transplantation data, four patients were excluded from the current analysis of the ESHOL dataset.

Given a large sample size, randomization is expected to create treatment groups that are on average comparable with respect to patient characteristics, i.e. treatment is independent of patient characteristics. Receiving a renal transplantation, however, may be dependent on patient characteristics. For example, younger patients with less co-morbidity are more likely to receive a renal transplantation. These patient characteristics are also predictive of the outcome (all-cause mortality). Since these patient characteristics are related to both transplantation and the outcome we will refer to them as confounders of the transplantation-outcome relation (See Figure 1).

While randomization is expected to achieve equal distributions of patient characteristics between treatment arms, in reality differences in patient characteristics may actually be present. Adjustment for variables related to the outcome will remove any remaining confounding by observed variables and tends to improve power in all mentioned methods of analysis [10].

Methods to analyze dialysis trials in the presence of renal transplantation

We compared five methods to handle renal transplantation in dialysis trials. These methods are described in more detail below and summarized in Table 1.

1 Intention-to-treat (ITT) analysis

In ITT analysis, patients are analyzed according to the treatment group they are allocated to. This analysis ignores the fact that a subgroup of patients received a renal transplantation and stopped the allocated treatment. We are not taking into account other forms of treatment switching (e.g. from HD to HDF or the other way around). Since the equal distributions of patient characteristics (including those also associated with the outcome) between treatment groups obtained by randomization remains intact, ITT analysis allows for unbiased effect estimation. The ITT estimate is interpreted as the effect of the treatment *strategy*; implying that renal transplantation during the follow-up period of the trial is an inherent part of the treatment strategy. In other words, results from the current study will not be applicable to a future population in which the proportion of patients receiving a renal transplantation and / or the patient characteristics of those receiving a transplantation (i.e. the *strategies*) differ from those in the current trial. ITT treatment effects are sometimes called pragmatic or *total effects*, since the ITT estimate includes the effect treatment has through changing the probability of receiving additional interventions (including here a renal transplantation) after the treatment has been initiated.

2 Per protocol exclusion (PP_{excl}) analysis

Similar to ITT analysis, in PP analysis patients are analyzed according to the treatment group they were allocated to. However, in PP_{excl} analysis those subjects who stop receiving their allocated treatment after receiving a renal transplantation, are excluded from the analysis. The PP estimate is interpreted as the effect of treatment in the subset of patients that complete the trial according to protocol (here, non-transplanted patients). Besides the fact that renal transplantation improves survival, patients receiving renal transplantation have a different prognosis (e.g. these patients are on average younger) compared to patients who remain on treatment, therefore PP analyses are biased in case transplantation occurs more often in one of the treatment groups [1, 11]. However, when these prognostic differences (i.e. confounders of the transplantation-outcome relation) are adjusted for, the estimated treatment effect should be unbiased, provided no other sources of bias exist [1].

3 Per protocol censoring (PP_{cens}) analysis

In a PP_{cens} analysis, patients receiving a renal transplantation are not excluded from the analysis (as in the PP_{excl} analysis), but censored (i.e. considered excluded without developing the outcome) at the time they receive the transplantation. Similar to PP_{excl} , PP_{cens} analyses are biased in case transplantation occurs more often in one of the treatment groups and the reasons for this are associated with the outcome. However, the bias is less pronounced compared with PP_{excl} , since patient-time until transplantation is still accounted for in the analysis. Again, adjustment for confounding leads to an unbiased effect estimate, provided no other sources of bias exist.

4 Including transplantation in the outcome model, transplantation adjusted (TA) analysis

Treatment effects obtained by ITT and PP may be of limited generalizability. Specifically, PP effects are only applicable to patients who do not receive transplantation, and ITT effects are only generalizable to populations with a comparable percentage and allocation mechanism of transplantation. Therefore it may be of interest to estimate the *controlled direct effect* of treatment, which is the effect of treatment (i.e., dialysis) excluding the effect treatment has through changing the probability of receiving a renal transplantation (either by chance or through some causal, known or unknown, mechanism) [12]. The controlled direct effect of treatment assumes the same effect of treatment in patients receiving transplantation as well as non-transplanted patients [13]. The controlled direct effect is estimated by including transplantation in the outcome model. The transplanted-adjusted (TA) estimates can be interpreted as the biological effect of treatment on the outcome, independent of the effect of treatment through affecting the probability of a transplantation. Transplantation should be modelled as a time-dependent covariate in the outcome model [14, 15].

5 TA analysis adjusted for transplantation-outcome confounders (TA_{ext})

Since TA effect estimates are conditional on transplantation, the resulting effect estimates are prone to bias (as in the PP analysis). Therefore, it is necessary to adjust for transplantation-outcome confounders in the outcome model. The TA_{ext} effect may be biased if important confounders for the relationship between transplantation and the outcome are unmeasured or when observed confounders were not assessed correctly. In our analyses we adjusted for measured confounders: age, history of cardiovascular disease, serum creatinine, diabetes mellitus, hemoglobin, albumin, body surface area, months on dialysis and c-reactive protein.

Statistical analysis

R 3.0.1 (www.r-project.org) was used to perform the statistical analyses [16]. Before applying the five methods of analysis described above, missing data on transplantation-outcome confounders were imputed using multiple imputation by chained equations using the R-package “mice” [17]. Log transformations of months of dialysis and c-reactive protein were taken to comply with the assumption of normality, which is necessary for multiple imputation. Ten imputed datasets were created for each study. The R-package “survival” was used to fit the Cox proportional hazard (PH) models. Cox PH models were applied. When transplantation was included in the Cox PH model, it was included as a time-varying covariate in order to prevent immortal-time bias. Immortal-time bias is the result of classifying patient-time, before onset of treatment, as time on treatment. Because patients have to survive until they receive the treatment of interest, the misclassified time before the start of treatment is called immortal-time, and the resulting bias immortal-time bias [14, 15, 18, 19]. Results from the imputed datasets were combined using Rubin’s rule to obtain hazard ratios (HRs) and 95% confidence intervals (CI) [20], for which the function MIcombine from the package “mitools” was used. Log-log and Schoenfeld residual plots were obtained and checks for PH-assumptions were performed.

RESULTS

Baseline characteristics of patients enrolled in the ESHOL and CONTRAST studies are presented in Table 2. A total of 28,326 observation months from 902 patients were included in the analysis of the ESHOL study. The mean age of patients was 65.5 years (sd 14.3 years) and 298 (33.0%) had a history of cardiovascular disease. A total of 179 (19.8%) patients received a renal transplantation during follow-up, 101 (22.2%) HDF patients were transplanted compared to 78 (17.5%) HD patients. Missing covariate data were most common for c-reactive protein, which had missing entries for 211 (23.4%) patients. The CONTRAST study consisted of 26,398 observation months from 714 patients. The mean age of patients was 64.1 years (sd 13.7 years) and 313 (43.8%) had a history of cardiovascular disease. During follow-up, 151 (21.1%) patients received a renal transplantation, 78 (21.8%) HDF versus 73 (20.5%) HD patients were transplanted. Again, missing covariate data were most prevalent for c-reactive protein, on which 309 (43.3%) patients had missing entries.

As expected, in both ESHOL and CONTRAST, baseline characteristics of patients receiving transplantation during follow up differed from patients who did not receive a renal transplant (Table 2). In the non-transplanted patient group of the ESHOL study, treatment groups differed with respect to history of cardiovascular disease (HD 38.0%, HDF 34.9%) and diabetes mellitus status (HD 29.3%, HDF 25.4%). In the CONTRAST study, transplantation-outcome confounders were comparable in the two treatment groups. For example, the prevalence of a history of cardiovascular disease (HD 50.9% vs HDF 48.6%) and diabetes mellitus (25.2% HD vs 26.8% HDF) were similar.

Table 3 shows the effect of HDF treatment against HD treatment on all-cause mortality, when applying different analytical methods in the two studies. In ESHOL, the effect of HDF vs HD treatment was estimated to be HR 0.76 (95%CI 0.59-0.97) for the unadjusted ITT. In CONTRAST, the effect of HDF vs HD treatment was estimated to be HR 0.95 (95%CI 0.75-1.20) for the unadjusted ITT.

Unadjusted PP analysis of the ESHOL study resulted in HR 0.73 (95% CI 0.56-0.94) and HR 0.74 (95%CI 0.58-0.96) for censoring (PP_{cens}) and exclusion (PP_{excl}), respectively. In the CONTRAST study, the unadjusted PP analyses resulted in HR 0.88 (95%CI 0.69-1.13) and HR 0.90 (95%CI 0.70-1.16) for PP_{cens} and PP_{excl}, respectively.

In ESHOL, TA analysis resulted in HR 0.77 (95%CI 0.60-0.99), while TA analysis in the CONTRAST study resulted in HR 0.95 (95%CI 0.75-1.21). In ESHOL, TA analysis with adjustment for transplantation-outcome confounders (TA_{ext}) resulted in HR 0.80 (95%CI 0.62-1.02), while the same analysis in the CONTRAST study resulted in HR 0.89 (95%CI 0.69-1.13).

DISCUSSION

This study assessed whether differences in published effect estimates observed between two RCTs (ESHOL and CONTRAST) investigating the effect of HDF versus HD on mortality in end-stage renal disease could be attributed to the fact that these RCTs applied different methods of analyzing the occurrence of renal transplantation during the trial. Indeed, the differences in effects between the two studies attenuated when the same analysis was performed; especially adjustment for transplantation-outcome confounders led to more similar effect estimates between the ESHOL and CONTRAST trials. This indicates that differences in applied analytical methods explain part of the differences in effects observed between these trials. Our analyses exemplify the necessity of taking competing treatments into accounting when evaluating effects of therapeutic interventions in randomized trials.

Strengths and limitations

One of the strengths of our study is that by using the original individual patient data we were able to compare different methods of analysis in the same data, such that differences in results obtained are likely due to the method applied. However our study is limited by the fact that, apart from the method of analysis, varying results between RCTs in end stage renal disease patients may be explained by other factors, such as differences in patient characteristics, random sampling variability, variation between practices, and the dosage/intensity of the delivered intervention as has been discussed at length in the literature [2][5][21]. These issues are beyond the scope of this paper.

In the current analysis, only confounders (patient characteristics) that were measured at baseline were considered. Adjustment for baseline patient characteristics ignores the fact that patient characteristics, including confounders of the transplantation-outcome relation, may change over time. When treatment affects future patient characteristics and these (intermediate) patient characteristics increase the probability of transplantation, adjusted TA analysis adjusting for baseline transplantation-outcome confounders only may be biased, since these patient characteristics may

have changed over time. However, adjustment for time-varying transplantation-outcome confounders affected by prior treatment (dialysis) should not be performed using standard methods such as stratification or regression analysis [6, 22]. In that case, advanced methods, such as inverse probability of treatment weighting (IPTW), G-computation, or G-estimation, could be used to obtain unbiased effect estimates. Additionally, treatment by competing treatment interactions may need to be explored [13].

Choosing the direct effect of HDF (TA_{ext}) over a pragmatic effect (ITT)

In practice, we often want to estimate the effect of the package of care a ESRD patient receives (including either HDF or HD) on the risk of mortality. It seems that this effect is estimated by the total effect of HDF compared to HD, based on an ITT analysis, which includes the increase in transplantation likelihood, and through that a reduction in the risk of mortality. However, when we assume that HDF and HD patients within a particular trial are competing for receiving a transplantation due to the limited amount (e.g. they are fishing in the same pool) of available renal donors, the estimated ITT effect may differ from the effect that will be encountered in the population receiving future daily practice (i.e. in the target population). In other words, the ITT effect may not exist outside the trial environment. We will try to illustrate this using some figures from the ESHOL trial. In the ESHOL trial, a total of 179 (19.8%) patients received a renal transplantation during follow-up; relatively more patients in the HDF group (22.2%) received transplantation compared to the HD group (17.5%). Therefore, part of the observed ITT effect comparing HDF to HD is due to the larger percentage of renal transplantation in the HDF group. However, when we assume that the total number of transplantations performed in that population does not increase under HDF treatment (it is unlikely that the number of transplantations will increase, since the number of transplantations performed is limited by the amount of donors available and this amount is unrelated to the treatment at hand) we expect 19.8% of patients to receive a transplantation if we decide to treat the target population with one of the two strategies (HDF or HD). This would mean that an expected 19.8% of patients on HDF treatment will receive a transplantation and similarly in the same population on HD treatment also an expected 19.8% of patients will receive a transplantation. Therefore, the indirect effect of HDF included in the ITT effect (i.e., the effect of HDF on the risk of mortality through increasing the likelihood of transplantation relative to HD within a trial) will not provide health benefits in the target population, since the total number of transplantations performed under HDF does not increase compared to the situation in which all patients are treated with HD. In other words, the effect of HDF treatment in the target population is different from the effect estimated by ITT analysis in a trial, because the indirect effect of HDF does

not exist in the target population. Therefore, models such as TA_{ext} should be applied that assess the direct effect of HDF on the risk of mortality. With the following exaggerated example we wish to further illustrate our point. Imagine the situation that a total of 20% of trial patients receive a transplantation, relatively more (40%) of patients in the HDF group received a transplantation compared to (0%) in the HD group. Again the ITT effect will indicate benefits of HDF compared to HD, largely due to the indirect effect caused by the transplantations performed in the HDF group and partly due to the direct effect of HDF on mortality. However, when HDF would be applied to all patients in the target population, 20% of HDF patients will receive a transplantation and when we compare their outcome to the outcome of the same population under HD treatment in which also 20% would receive transplantation we would conclude that part of the indirect effect observed in the trial remains unobserved in the target population.

Additionally, the replicability of the ITT effect in another study is compromised when other study populations have different proportions of patients receiving renal transplantation and/or the patient characteristics of those receiving transplantation differ from those in the current trial. It may be easier to generalize the effects of HDF vs HD based on their direct effects on mortality. Therefore, of the methods we considered, the direct effect of HDF on mortality estimated by TA_{ext} can be considered most generalizable to populations where the proportions of patients receiving renal transplantation and/or the patient characteristics of those receiving transplantation differ from those in the ESHOL and the CONTRAST trial.

Hence, the reasons for choosing the direct effect (TA_{ext}) of HDF over a pragmatic effect (ITT) are twofold. First, the ITT effect consists of a comparison between treatment groups within a trial. Therefore, if one group receives more transplantations, the other necessarily receives less. This situation does not exist outside the trial environment, therefore the ITT effect may differ from the effect that will be observed in the target population. . Second, the replicability of the ITT effect is compromised when other study populations have different proportions of patients receiving renal transplantation and/or the patient characteristics of those receiving transplantation differ from those in the current trial. However, the TA_{ext} effect may be biased if important confounders for the relationship between transplantation and the outcome are unmeasured or when observed confounders were not assessed correctly. Therefore we propose to report both TA_{ext} and ITT treatment effect estimates to allow for a comparison and to assess the impact of secondary interventions.

Conclusion

The apparent differences in estimated treatment effects between two dialysis trials were to a large extent attributable to differences in applied methodology for taking renal transplantation into account in their final analyses. Our results exemplify the necessity of careful consideration of the treatment effect of interest when estimating therapeutic effect in randomized controlled trials in which participants may receive additional treatments.

ACKNOWLEDGEMENTS

The pooling project was funded by EuDial, the dialysis subcommittee of the European Renal Association – European Dialysis & Transplant Association.

Conflict of Interest Statement:

None of the authors declared a conflict of interest

REFERENCES

- [1] Groenwold R, Moons K, Vandenbroucke JP. Randomized trials with missing outcome data: how to analyze and what to report. *CMAJ: Canadian Medical Association journal= journal de l'Association medicale canadienne*. 2014;186(15):1153–1157.
- [2] Mostovaya IM, Blankestijn PJ, Bots ML, Covic A, Davenport A, Grooteman MP, et al. Clinical Evidence on Hemodiafiltration: A Systematic Review and a Meta-analysis. In: *Seminars in dialysis*. vol. 27. Wiley Online Library; 2014. p. 119–127.
- [3] Grooteman MP, van den Dorpel MA, Bots ML, Penne EL, van der Weerd NC, Mazairac AH, et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. *Journal of the American Society of Nephrology*. 2012;23(6):1087–1096.
- [4] Maduell F, Moreso F, Pons M, Ramos R, Mora-Macià J, Carreras J, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. *Journal of the American Society of Nephrology*. 2013;24(3):487–497.
- [5] Peters SA, Bots ML, Canaud B, Davenport A, Grooteman MP, Kircelli F, et al. Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials. *Nephrology Dialysis Transplantation*. 2016;31(6):978–984.
- [6] Hernán MA, Hernández-Dáz S, Robins JM. A structural approach to selection bias. *Epidemiology*. 2004;15(5):615–625.
- [7] Davenport A, Peters SA, Bots ML, Canaud B, Grooteman MP, Ascí G, et al. Higher convection volume exchange with online hemodiafiltration is associated with survival advantage for dialysis patients: the effect of adjustment for body size. *Kidney international*. 2016;89(1):193–199.
- [8] Penne EL, Blankestijn PJ, Bots ML, van den Dorpel MA, Grooteman MP, Nubé MJ, et al. Effect of increased convective clearance by on-line hemodiafiltration on all cause and cardiovascular mortality in chronic hemodialysis patients – the Dutch CONvective TRANsport Study (CONTRAST): rationale and design of a randomised controlled trial [ISRCTN38365125]. *Current controlled trials in cardiovascular medicine*. 2005;6(1):1.

- [9] Maduell F, Moreso F, Mora-Macià J, Pons M, Ramos R, Carreras J, et al. ESHOL study reanalysis: All-cause mortality considered by competing risks and time-dependent covariates for renal transplantation. *Nefrologia*. 2016; 36 (2): 156-163.
- [10] Hernández AV, Eijkemans MJ, Steyerberg EW. Randomized controlled trials with time-to-event outcomes: how much does prespecified covariate adjustment increase power? *Annals of epidemiology*. 2006;16(1):41–48.
- [11] Kalbfleisch JD, Prentice RL. *The statistical analysis of failure time data*. vol. 360. John Wiley & Sons; 2011.
- [12] Li L, Hu B, Kattan MW. Modeling potential time to event data with competing risks. *Lifetime data analysis*. 2014;20(2):316–334.
- [13] Vansteelandt S. Estimating direct effects in cohort and case–control studies. *Epidemiology*. 2009;20(6):851–860.
- [14] Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. *Bmj*. 2010;340:b5087.
- [15] Suissa S. Immortal time bias in observational studies of drug effects. *Pharmacoepidemiology and drug safety*. 2007;16(3):241–249.
- [16] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2012. ISBN 3-900051-07-0; 2012.
- [17] van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*. 2011;45(3):1–67. Available from: <http://www.jstatsoft.org/v45/i03/>.
- [18] Shintani AK, Girard TD, Arbogast PG, Moons KG, Ely EW. Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. *Critical care medicine*. 2009;37(11):2939–2945.
- [19] Stricker BC, Stijnen T. Analysis of individual drug use as a time-varying determinant of exposure in prospective population-based cohort studies. *European journal of epidemiology*. 2010;25(4):245–251.

[20] Therneau TM. A Package for Survival Analysis in S; 2015. Version 2.38. Available from: <http://CRAN.R-project.org/package=survival>.

[21] Tattersall JE, Ward RA, Canaud B, Blankestijn PJ, Bots M, Covic A, et al. Online haemodiafiltration: definition, dose quantification and safety revisited. *Nephrology Dialysis Transplantation*. 2013;28(3):542–550.

[22] Daniel R, Cousens S, De Stavola B, Kenward M, Sterne J. Methods for dealing with time-dependent confounding. *Statistics in medicine*. 2013;32(9):1584–1618.

TABLES

TABLE 1 Methods to deal with transplantation during follow-up (competing treatment) in randomized trials of hemodialysis			
Method	Description	Interpretation of effect estimate	Potential for bias
Intention to treat (ITT)	Data of all patients is used. Treatment status is analyzed as allocated. Transplantation is ignored in the analysis.	The effect of treatment in settings with rates and allocation mechanisms of transplantation similar to the current trial.	Unbiased when randomization is successful.
Per protocol (PP) (Exclusion)	Exclude patients who receive transplantation from the analysis.	The effect of treatment in the group that completes the trial according to protocol (i.e. patients who do not receive transplantation). In other words, the effect of treatment in non-transplanted patients.	This effect is biased when both treatment affects the probability to receive transplant and transplantation-outcome confounders are present. Bias can be avoided by adjusting for transplantation-outcome confounders.
Per protocol (PP) (Censored)	Censor patients who receive transplantation at transplantation (follow-up info after transplantation is discarded).	See per protocol exclusion. Difference is that we gain the patient-time until transplantation for patients receiving transplantation. This may lead to narrower confidence intervals.	See per protocol exclusion.
Accounting for transplant as time-dependent covariate (TA)	Transplantation is added to the outcome model as a time-dependent covariate.	The effect of treatment in transplanted and non-transplanted patients.	This effect is biased when treatment affects the probability to receive transplant and there are transplantation-outcome confounders. Bias can be avoided by adjusting for transplantation-outcome confounders.
Accounting for transplant as time-dependent covariate and adjustment for transplantation-outcome confounders (TA_{ext})	Transplantation is added to the outcome model as a time-dependent covariate. Additionally, confounders of the transplantation outcome relationship are included in the model for the outcome.	The effect of treatment in transplanted and non-transplanted patients.	The TA _{ext} effect is biased when important transplantation-outcome confounders are unmeasured or unknown and therefore cannot be adjusted for.

In RCTs comparing hemodiafiltration (HDF) with hemodialysis (HD) on the risk of mortality among patients with end stage kidney disease (ESKD), during follow-up a subset of patients may receive a non-randomly allocated competing treatment (i.e. a renal transplantation) that effectively improves patient outcome.

TABLE 2 Baseline characteristics of patients in CONTRAST and ESHOL

	CONTRAST						ESHOL					
	All patients n=714		Transplanted n=151 (21.1%)		Non-transplanted n= 563 (78.9%)		All patients n=902		Transplanted n= 179 (19.8%)		Non-transplanted n= 723 (80.2%)	
	no. missing values	Overall	HD n=73	HDF n=78	HD n=283	HDF n=280	no. missing values	Overall	HD n=78	HDF n=101	HD n=368	HDF n=355
Male sex, n(%)	0	445 (62.3%)	44 (60.3%)	44 (56.4%)	187 (66.1%)	170 (60.7%)	0	602 (66.7%)	48 (61.5%)	71 (70.3%)	237 (64.4%)	246 (69.3%)
Age, mean (sd)	0	64.1 (13.7)	55.9 (11.4)	51.1 (12.8)	66.1 (13.1)	67.7 (12.0)	0	65.5 (14.3)	52.7 (13.0)	55.5 (11.6)	69.4 (12.8)	67.1 (14.0)
History of cardiovascular disease, n (%)	0	313 (43.8%)	18 (24.7%)	15 (19.2%)	144 (50.9%)	136 (48.6%)	0	298 (33.0%)	14 (18.0%)	20 (19.8%)	140 (38.0%)	124 (34.9%)
Serum creatinine (mg/dL), mean (sd)	3	9.74 (2.90)	11.15 (2.62)	11.12 (2.65)	9.63 (2.82)	9.09 (2.87)	33	8.02 (2.38)	8.25 (2.32)	8.90 (2.43)	7.91 (2.39)	7.83 (2.33)

Diabetes mellitus, n (%)	25	177 (24.8%)	12 (16.2%)	19 (24.4%)	71 (25.2%)	75 (26.8%)	0	226 (25.0%)	13 (16.7%)	14 (13.9%)	108 (29.3%)	90 (25.4%)
Hemoglobin (g/dL), mean (sd)	1	11.8 (1.25)	11.8 (0.99)	12 (1.26)	11.7 (1.22)	11.8 (1.34)	2	12.0 (1.43)	12.1 (1.28)	12.4 (1.37)	11.9 (1.44)	11.9 (1.46)
Albumin (g/dL), mean (sd)	9	4.04 (0.39)	4.17 (0.43)	4.10 (0.29)	4.03 (0.38)	4.00 (0.40)	24	4.09 (0.43)	4.20 (0.44)	4.21 (0.43)	4.03 (0.44)	4.08 (0.42)
Body surface area (m²), mean (sd)	0	1.85 (0.21)	1.87 (0.20)	1.83 (0.21)	1.87 (0.20)	1.84 (0.23)	1	1.73 (0.19)	1.73 (0.18)	1.76 (0.18)	1.72 (0.19)	1.74 (0.19)
Log(months on dialysis), mean (sd)	0	3.22 (0.87)	3.42 (0.83)	3.12 (0.81)	3.22 (0.88)	3.20 (0.88)	3	3.32 (1.14)	3.01 (1.00)	3.22 (1.18)	3.38 (1.17)	3.36 (1.12)
Log(c-reactive protein), mean (sd)	309	1.70 (1.06)	1.52 (1.02)	1.43 (1.03)	1.71 (1.05)	1.82 (1.12)	211	2.09 (0.92)	1.86 (0.93)	1.92 (0.91)	2.13 (0.90)	2.14 (0.96)

Due to the nature of MI and rounding of numbers, the separate DM categories do not sum to the overall DM count.

TABLE 3 Estimates of the hazard ratio (HR) of hemodiafiltration (HDF) versus hemodialysis (HD) for all-cause mortality for different methods in two RCTs: ESHOL and CONTRAST		
	ESHOL	CONTRAST
Method	HR (95% CI)	HR (95% CI)
Intention to treat (ITT)	0.76 (0.59-.97)	0.95 (0.75-1.20) ^{§CONTRAST}
Per protocol (PP) (Censored)	0.73 (0.56-0.94) ^{§ESHOL}	0.88 (0.69-1.13)
Per protocol (PP) (Exclusion)	0.74 (0.58-0.96)	0.90 (0.70-1.16)
Accounting for transplant as a time-dependent covariate (TA)	0.77 (0.60-0.99)	0.95 (0.75-1.21)
Accounting for transplant as a time-dependent covariate and adjustment for transplantation-outcome confounders (TA_{ext})	0.80 (0.62-1.02)	0.89 (0.69-1.13)

[§]original ESHOL and CONTRAST analyses. For the current analyses, the ESHOL dataset was completed by adding follow-up data on all-cause mortality for those patients who had discontinued randomized treatment (received a renal transplant) and were considered alive in the previously published analyses. In the current analysis 4 subjects were excluded due to missing data).

FIGURES




Figure 1. Causal diagram of renal transplantation in randomized controlled trials of dialysis modalities.

When treatment is related to receiving a transplantation, and patient characteristics (transplantation-outcome confounders) are related to both transplantation as well as experiencing the outcome. Selection bias arises when only patients who did not receive a transplantation are selected for analysis (or similarly, when we condition on-, or adjust for-transplantation). Since patient characteristics for patients receiving a transplantation are different from those who do not receive a transplantation. And a different proportion of patients in each treatment group receives a transplantation, the remaining treatment groups are no longer comparable on these transplantation-outcome confounders. The induced bias is a result of selection of patients for analysis (i.e. non-transplanted patients) which is different between treatment groups (i.e. patients in the treatment group are more likely to receive transplantation), and is therefore called selection bias. Depending on the method of analysis, this may bias the estimated treatment effect.

The HDF Pooling Project investigators:

ESHOL investigators: Francisco Maduell, Francesc Moreso, Mercedes Pons, Rosa Ramos, Josep Mora-Macià, Jordi Carreras, Jordi Soler, Ferran Torres, Josep M. Campistol, and Alberto Martinez-Castelao M. Pons, B. Insensé, C. Perez, and T. Feliz (CETIRSA, Barcelona); R. Ramos, M. Barbeta, and C. Soto (Hospital San Antonio Abad, Vilanova i la Geltru); J. Mora, A. Juan, and O. Ibrik (Fresenius Medical Care, Granollers); A. Foraster and J. Carreras (Diaverum Baix Llobregat, Hospitalet); F. Moreso, J. Nin, and A. Fernández (Fresenius Medical Care, Hospitalet); J. Soler, M. Arruche, C. Sánchez, and J. Vidiella (Fresenius Medical Care, Reus); F. Barbosa, M. Chiné, and S. Hurtado (Fresenius Medical Care Diagonal, Barcelona); J. Llibre, A. Ruiz, M. Serra, M. Salvó, and T. Poyuelo (CETIRSA, Terrassa); F. Maduell, M. Carrera, N. Fontseré, M. Arias, and Josep M. Campistol (Hospital Clínic, Barcelona); A. Merín and L. Ribera (Fresenius Medical Care Julio Verne, Barcelona); J.M. Galceran, J. Mòdol, E. Moliner, and A. Ramirez (Fundació Althaia, Manresa); J. Aguilera and M. Alvarez (Hospital Santa Tecla, Tarragona); B. de la Torre and M. Molera (Diaverum Bonanova, Barcelona); J. Casellas and G. Martín (Diaverum IHB, Barcelona); E. Andres and E. Coll (Fundació Puigvert, Barcelona); M. Valles and C. Martínez (Hospital Josep Trueta, Girona); E. Castellote (Hospital General, Vic); J.M. Casals, J. Gabàs, and M. Romero (Diaverum, Mataró); A. Martinez-Castelao and X. Fulladosa (Hospital Universitari Bellvitge, Hospitalet); M. Ramirez-Arellano and M. Fulquet (Hospital de Terrassa); A. Pelegrí, M. el Manouari, and N. Ramos (Diaverum Verge de Montserrat, Santa Coloma); J. Bartolomé (Centre Secretari Coloma, Barcelona); R. Sans (Hospital de Figueres); E. Fernández and F. Sarró (Hospital Arnau de Vilanova, Lleida); T. Compte (Hospital Santa Creu, Tortosa); F. Marco and R. Mauri (Diaverum Nephros, Barcelona); and J. Bronsoms (Clínica Girona), J.A. Arnaiz, H. Beleta, and A. Pejenuate (UASP Farmacología Clínica, Hospital Clínic Barcelona), F. Torres, J. Ríos, and J. Lara (Biostatistics Unit, School of Medicine, Universitat Autònoma de Barcelona)

CONTRAST investigators: P.J. Blankestijn, M.P.C. Grooteman, M.J. Nubé, P.M. terWee, M.L. Bots; M.A. van den Dorpel, Canada: Georges-L. Dumont Regional Hospital, Moncton: M. Dorval; CHUM St. Luc Hospital, Montréal: R. Lévesque. The Netherlands: Academic Medical Center, Amsterdam: M.G. Koopman; Catharina Hospital, Eindhoven: C.J.A.M. Konings; Dialysis Clinic Noord, Beilen: W.P. Haanstra; Dianet Dialysis Centers, Utrecht: M. Kooistra and B. van Jaarsveld; Franciscus Hospital, Roosendaal: T. Noordzij; Gelderse Vallei Hospital, Ede: G.W. Feith; Groene Hart Hospital, Gouda: H.G. Peltenburg; Haga Hospital, The Hague: M. van Buren; Isala Clinics, Zwolle: J.J.G. Offerman; Jeroen Bosch Hospital, Hertogenbosch: E.K. Hoogveen; Maasland Hospital, Sittard: F. deHeer; Maasstad Hospital, Rotterdam: P.J. van de Ven; Martini Hospital, Groningen: T.K. Kremer

Hovinga; Medical Center Alkmaar: W.A. Bax; Onze Lieve Vrouwe Gasthuis, Amsterdam: J.O. Groeneveld; Oosterschelde Hospital, Goes: A.T.J. Lavrijssen; Rijnland Hospital, Leiderdorp: A.M. chrander-Van der Meer; Rijnstate Hospital, Arnhem: L.J.M. Reichert; Slingeland Hospital, Doetinchem: J. Huussen; St. Elisabeth Hospital, Tilburg: P.L.Rensma; St. Fransiscus Gasthuis, Rotterdam: Y. Schrama; University Medical Center St. Radboud, Nijmegen: H.W. van Hamersvelt; University Medical Center Utrecht, Utrecht: W.H. Boer; VieCuri Medical Center, Venlo: W.H. van Kuijk; VU University Medical Center, Amsterdam: M.G. Vervloet; Zeeuws-Vlaanderen Hospital, Terneuzen: I.M.P.M.J. Wauters. Norway: Haukeland University Hospital, Bergen: I. Sekse.

Turkish HDF Study investigators: Ercan Ok, Gulay Asci, Huseyin Toz, Ebru Sevinc Ok, Fatih Kircelli, Mumtaz Yilmaz, Ender Hur, Meltem Sezis Demirci, Cenk Demirci, Soner Duman, Ali Basci, Siddig Momin Adam, Ismet Onder Isik, Murat Zengin, Gultekin Suleymanlar, Mehmet Emin Yilmaz and Mehmet Ozkahya Pinar Ergin, Alfert Sagdic, Erkan Kayali, Can Boydak, Taskin Colak, Sihli Caliskan, Hakan Kaplan, Hasibe Ulas, Sait Kirbiyik, Hakan Berktas and Necati Dilbaz

French HDF Study investigators: Bernard Canaud, Jean-Paul Cristol, Marion Morena, H el ene Leray-Moragues, Leila Chenine, Marie-Christine Picot, Audrey Jausset, Claire Belloc, M elodie Lagarrigue (University Hospital Center, Montpellier), Lotfi Chalabi (AIDER, Montpellier), Alain Debure, Messaoud Ouziala, Jean-Jacques Lefevre (ATS, St Denis), Damien Thibaudin, Hesham Mohey, Christian Broyet, Aida Afiani, (University Hospital Center, Saint Etienne), Marie-Odile Serveaux, Laure Patrier (University Hospital Center, N imes), Fran ois Maurice, Jean-Pierre Rivory (CHL, Castelnau le Lez), Philippe Nicoud (La Vall ee Blanche center, Chamonix), Claude Durand, Michel Normand (Saint Martin polyclinic, Pessac), Bruno Seigneuric (University Hospital Center, Toulouse), Eric Magnant (Centre H emodialyse Provence, Aix en Provence), Lynda Azzouz (Artic 42, St Priest en Jarez), Mohamed Shariful Islam, Sandor Vido (University Hospital Center, Nice), Hilaire Nzeyimana, Dani ele Simonin (ECHO Michel Ange center, Le Mans), Yamina Azymah, Ibrahim Farah, Jean-Philippe Coindre (Hospital center, Le Mans), Olivier Puyoo, Marie-H el ene Chabannier, Richard Ibos, Fabienne Rouleau (Centre N ephrologique d'Occitanie, Muret), Carlos Vela, Josiane Joule (Hospital center, Perpignan), Fran ois Combarrous (Tonkin clinic, Villeurbanne), C ecile Turc-Baron, Francis Ducret, Philippe Pointet, Isabelle Rey (Hospital center, Annecy), Jacky Potier (Hospital center, Cherbourg), Jean- Christophe Bendini, Franck Perrin (St Georges clinic, Nice), Kristian Kunz (University Hospital Center, Strasbourg), Ga elle Lefrancois, Ang elique Colin, Sophie Parahy, Irima Dancea, St ephanie Coupel, Angelo Testa (ECHO center, Rez e), Philippe Brunet, Ga etan Lebrun, Dominique Jaubert (University Hospital Center AP-

HM, Marseille), Catherine Delcroix, Frédéric Lavainne, Anne Lefebvre (University Hospital Center, Nantes), Marie-Paule Guillodo, Dominique Le Grignou (AUB, Brest), Assia Djema (Hospital center, Cholet), Mehadji Maaz, Sylvie Chiron (Hospital center, Colmar), Maxime Hoffmann, Pascale Depraetre (Louvière clinic, Lille), Atman Haddj-Elmrabet, Véronique Joyeux (University Hospital Center, Rennes), Dominique Fleury, Laurence Vrigneaud, Vincent Lemaitre (Hospital center, Valenciennes), Didier Aguilera, Abdallah Guerraoui (Hospital center, Vichy), Alain Cremault, Achour Laradi, Francois Babinet (ECHO Pole Santé Sud center, Le Mans)

Authors' Contributions

CMH, AWH and RHHG came up with the concept of the analyses. CMH and SAE performed the statistical analyses. CMH, SAE, MLB and RHHG drafted the reported. All authors contributed to the interpretation of the data, the preparation of the manuscript, and the decision to submit for publication. CMH, SAE, MLB, and RHHG vouch for the validity of the study and are responsible for the integrity of the work as a whole.

Financial contributors

The HDF Pooling project was designed, conducted, and analysed independently of the financial contributors of the individual studies as listed below. Study data were collected and retained by the investigators and were not available for the financial contributors of the individual studies. SAE and the meetings of the representatives of the combined authors of the four studies were financially supported by the EuDial working group. EuDial is an official working group of the European Renal Association – European Dialysis Transplant Association (ERA-EDTA, http://era-edta.org/eudial/European_Dialysis_Working_Group.html). No industry funding was received for any part of or activity related to the present analysis.

The Turkish HDF study was supported by European Nephrology and Dialysis Institute with an unrestricted grant. The study was performed in Fresenius Medical Care haemodialysis clinics in Turkey. ESHOL was supported by The Catalan Society of Nephrology and by grants from Fresenius Medical Care and Gambro through the Catalan Society of Nephrology. The CONTRAST study was supported by a grant from the Dutch Kidney Foundation (Nierstichting Nederland Grant C02.2019), and unrestricted grants from Fresenius Medical Care, Netherlands, and Gambro Lundia AB, Sweden. Additional support was received from the Dr. E.E. Twiss Fund, Roche Netherlands, the International

Society of Nephrology/ Baxter Extramural Grant Program, and the Netherlands Organization for Health Research and Development (ZONMw Grant 170882802). The French HDF study was supported by a national grant from the Health Ministry (Programme Hospitalier de Recherche Clinique, PHRC) as a mean to improve care and outcome of elderly chronic disease patients.